Sio Capital Management’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Sio Capital Management’s Portfolio IMNP Stock Details IMNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,883	Closed	-$79K	–	52
2016 Q2	$79K	Hold	9,883	–	–	0.04%	43
2016 Q1	$85K	Hold	9,883	–	–	0.03%	41
2015 Q4	$144K	Hold	9,883	–	–	0.06%	42
2015 Q3	$233K	Buy	+9,883	New	+$311K	0.16%	32

Other funds holding IMNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

EEG

E.E. Geduld $178M AUM 29.34% 1-Year Est. Return

IFS

Ifrah Financial Services Little Rock, Arkansas $378M AUM 17.57% 1-Year Est. Return

Sio Capital Management's IMNP Position: Q3 2016 in Review

Sio Capital Management sold out of Immune Pharmaceuticals Inc. (IMNP) in Q3 2016, closing a stake of 9,883 shares — an estimated $79K sold.

Sio Capital Management first reported a position in IMNP in Q3 2015 and held it in 4 quarters. The position peaked at $233K in Q3 2015. 14 funds tracked by Wall St. Rank hold IMNP as of Q3 2016.

Sio Capital Management reported no remaining Immune Pharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
Sio Capital Management sold 9,883 Immune Pharmaceuticals Inc. shares in Q3 2016, an estimated $79K.
Sio Capital Management first reported a position in Immune Pharmaceuticals Inc. in Q3 2015 and held it in 4 quarters.
Sio Capital Management's Immune Pharmaceuticals Inc. position peaked at $233K in Q3 2015.
14 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q3 2016.

Based on Sio Capital Management's 13F filing for Q3 2016, filed 15 Nov 2016.